| 1.7 -0.195 (-10.29%) | 04-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.43  |
1-year : | 2.75 |
| Resists | First : | 2.08 |
Second : | 2.35 |
| Pivot price | 1.99 |
|||
| Supports | First : | 1.64 |
Second : | 1.37 |
| MAs | MA(5) : | 1.87 |
MA(20) : | 2.01 |
| MA(100) : | 1.73  |
MA(250) : | 1.22 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 16 |
D(3) : | 22.4 |
| RSI | RSI(14): 34.1 |
|||
| 52-week | High : | 2.66 | Low : | 0.4 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ALXO ] has closed below the lower bollinger band by 7.2%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 8.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.92 - 1.93 | 1.93 - 1.93 |
| Low: | 1.62 - 1.63 | 1.63 - 1.65 |
| Close: | 1.68 - 1.7 | 1.7 - 1.72 |
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
Sat, 04 Apr 2026
ALXO Technical Analysis & Stock Price Forecast - Intellectia AI
Fri, 27 Mar 2026
ALX Oncology Holdings (ALXO) price target increased by 38.00% to 4.69 - MSN
Mon, 23 Mar 2026
ALX Oncology (ALXO) CEO sells 12,311 shares to cover tax obligations - Stock Titan
Wed, 18 Mar 2026
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Thu, 12 Mar 2026
Alx Oncology Faces Renewed Nasdaq Listing Risk After Prior Minimum Bid Price Violation - The Globe and Mail
Sun, 01 Mar 2026
ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones (NASDAQ:ALXO) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 132 (M) |
| Shares Float | 104 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 40.2 (%) |
| Shares Short | 1,220 (K) |
| Shares Short P.Month | 1,170 (K) |
| EPS | -1.9 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.47 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -61 % |
| Return on Equity (ttm) | -145.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -84 (M) |
| Levered Free Cash Flow | -51 (M) |
| PE Ratio | -0.9 |
| PEG Ratio | 0 |
| Price to Book value | 3.54 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|